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Abstract
Background—Sirolimus, an immunosuppressant agent used in renal transplantation, can prevent 
allograft rejection. Identification of the therapeutic index (ratio of minimum toxic concentration to 
minimum therapeutic concentration) for immunosuppresants is necessary to optimize the care of 
patients and set standards for bioequivalence evaluation of sirolimus products. However, the 
therapeutic index for sirolimus has been inconsistently defined, potentially due to inconsistencies 
in sirolimus exposure-response relationships.
Methods—The authors used retrospective therapeutic drug monitoring data from the electronic 
health records of patients treated in a tertiary healthcare system from 2008 to 2014, to: 1) develop 
a population pharmacokinetic model, 2) use the model to simulate sirolimus concentrations, and 3) 
characterize the exposure-response relationship. Using Wilcoxon rank-sum and Fisher’s exact 
tests, the authors determined relationships between sirolimus exposure and adverse events 
(anemia, leukopenia, thrombocytopenia, hyperlipidemia, decline in renal function) and the 
composite efficacy endpoint of graft loss or rejection.
Results—The developed 2-compartment population pharmacokinetic model showed appropriate 
goodness of fit. In a late-phase (>12 months), post-renal transplant population of 27 inpatients, the 
authors identified statistically significant relationships between 83 simulated peak and trough 
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sirolimus concentrations and outcomes: graft loss or rejection (p=0.018), and decline in renal 
function (p=0.006), respectively.
Conclusions—Use of therapeutic drug monitoring results and pharmacokinetic modeling 
permitted correlation of sirolimus concentrations with graft loss or rejection, and decline in renal 
function. However, the method was limited in its assessment of other adverse events. To better 
evaluate sirolimus exposure-response relationships, the method should be applied to a larger 
sample of newly-transplanted patients with a higher propensity toward adverse events or efficacy 
failure.
Keywords
sirolimus; pharmacokinetics; pharmacodynamics; anemia; thrombocytopenia; adverse event; 
efficacy
INTRODUCTION
Sirolimus is an immunosuppressive agent that inhibits antibody production and T-
lymphocyte activation and proliferation. Approved by the Food and Drug Administration 
(FDA) since 1999, sirolimus is indicated for the prevention of allograft rejection in patients 
13 years and older with a transplanted kidney.1 According to existing evidence, sirolimus is 
efficacious as a sole immunosuppressive agent in preventing organ rejection, when 
administered at doses of 1 to 4.2 mg/day.2,3 The product label currently recommends doses 
of 1 to 6 mg/day, with up to 7 mg/day administered to those with high immunologic risk.3
Despite a narrow recommended dosing range, previous studies indicate significant intra- and 
inter-individual variability in sirolimus pharmacokinetic (PK) parameters and resultant 
exposures in patients on chronic treatment with sirolimus.4,5 Because of the observed 
variability in sirolimus exposure, current recommendations suggest dose titration to achieve 
trough concentrations of 12 to 24 μg/L, often dependent on time since transplantation.2,3,6 
Importantly, titration of sirolimus dosing based on trough concentrations alone does not take 
into account drug toxicity. Previous investigators have identified significant adverse events 
(AEs), including bone marrow suppression, hyperlipidemia, diabetes mellitus, renal 
dysfunction, pneumonitis, and others, that occur despite administration within the 
recommended dose range and achievement of therapeutic sirolimus concentrations.7-12
Previous investigators have not consistently defined the therapeutic index (the ratio of 
minimum toxic concentration to minimum therapeutic concentration) of sirolimus.2-4 The 
current FDA product specific draft guidance for sirolimus states that the range between 
sirolimus therapeutic and toxic whole blood concentrations is narrow. However, a definitive 
conclusion on the therapeutic index was not reported. Therefore, we aimed to determine 
whether the use of sirolimus concentrations obtained through therapeutic drug monitoring in 
a cohort of renal transplant patients could be used to develop a population PK model for 
sirolimus. We aimed to use such a model to link simulated exposures with efficacy or AEs in 
the same cohort of patients, and to determine whether this combined methodology will 
better define sirolimus exposure-response relationships that could help define the therapeutic 
index of sirolimus.
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MATERIALS AND METHODS
Database/Patient population
We included patients ≥18 years of age treated with oral sirolimus to prevent allograft 
rejection following renal transplantation. Eligible participants were inpatient or seen at an 
outpatient clinic in the Duke University Health System between January 2008 and July 
2014, and had at least 1 recorded sirolimus concentration in the medical record. We 
excluded patients without any electronically available dosing records. We identified 
qualifying patients and data using an electronic data warehouse containing information from 
all operational systems serving the medical center’s hospitals and clinics. We reviewed and 
extracted the following data from the data warehouse: patient demographics, drug levels, and 
other lab results. We verified drug dosing and changes in dosing, concomitant medications 
of interest, safety data, and clinical outcomes through direct review of electronic medical 
records. The Duke University Institutional Review Board and FDA Research Involving 
Human Subjects Committee approved the study with a waiver of informed consent.
Standard procedures for analysis of sirolimus blood samples
Sirolimus samples obtained within the Duke University Health System were collected in 
whole blood EDTA containers and transferred to the Mayo Clinic Laboratories in Rochester, 
MN. Blood samples underwent protein precipitation, and the resultant supernatant was 
analyzed by high performance liquid chromatography-tandem mass spectrometry. The lower 
limit of quantification for the assay was 2 ng/mL and the precision of the assay was <10% 
throughout the analytical range. (Mayo Clinic Laboratories, personal communication)
Population PK analysis
We analyzed sirolimus whole blood PK data with a nonlinear mixed effects modeling 
approach using the software NONMEM (version 7.2, Icon Solutions, Ellicott City, MD, 
USA). We used first-order conditional estimation method with interaction (FOCE-I) for all 
model runs and performed run management using Pirana (version 2.8.1).13 We then 
performed visual predictive checks and bootstrap methods with Perl-speaks-NONMEM 
(version 3.6.2).14 We performed data manipulation and visualization using the software 
STATA (version 13.1, College Station, TX), R (version 3.0.2, R Foundation for Statistical 
Computing, Vienna, Austria) and RStudio (version 0.97.551, RStudio, Boston, MA, USA) 
packages, including lattice, Xpose and ggplot2.15
We evaluated one- and two-compartment PK models in NONMEM. We assessed between-
subject variability (BSV) for PK model parameters using an exponential relationship. In 
addition to BSV, we assessed between-occasion variability (BOV) for PK model parameters 
using an exponential relationship. Proportional, additive, and combined (proportional plus 
additive) residual error models were evaluated.
We visually inspected the potential effect of covariates on PK parameters by creating scatter 
and box plots (continuous and categorical variables, respectively) for the following 
covariates: age, body weight, serum creatinine, hematocrit, gender, race, and presence of ≥1 
concomitant medication of interest with known PK interaction with sirolimus (i.e., 
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diltiazem, cyclosporine, erythromycin, ketoconazole, rifampin, verapamil). We normalized 
continuous covariates to the population median. For continuous covariates, we used power 
function to describe covariate relationships on PK parameters. We used a forward inclusion 
(p<0.05 and delta objective function value (Δ OFV) >3.8) and backward elimination 
(p<0.001 and ΔOFV >10.8) approach to evaluate statistical significance of relevant 
covariates. Missing clinical data was imputed using the last value carried forward.
Population PK model evaluation and validation
During the population PK model building process, successful minimization, diagnostic plots, 
plausibility and precision of parameter estimates, as well as objective function and shrinkage 
values, were used to assess model appropriateness. We evaluated parameter precision other 
than the absorption rate constant and lag time for the final population PK model using non-
parametric bootstrapping (1000 replicates) to generate the 95% confidence intervals for 
parameter estimates. We performed standardized visual predictive check, using the final 
model to generate 1000 Monte Carlo simulation replicates per time point of sirolimus 
exposure. We then compared subject-level simulated results with observed values by 
calculating and plotting the percentile of each observed concentration in relation to its 1000-
simulated observations.16 The dosing and covariate values used to generate the simulations 
in the visual predictive check were the same as those used in the study population.
Relationship between sirolimus exposure and efficacy or AEs
We identified the following AEs of interest based on the drug FDA label: anemia (male: 
hematocrit <0.39; female: hematocrit <0.35), thrombocytopenia (platelets <150 ×103/ml), 
leukopenia (white blood cell count <3.2 ×103/ml), hypercholesterolemia (total cholesterol 
>199 mg/dL), hypertriglyceridemia (triglycerides >149 mg/dL), and decline in renal 
function (25% increase in serum creatinine during an admission or clinician documentation 
noting worsening function). Efficacy was assessed through the composite outcome of graft 
loss, and biopsy-proven rejection. We used our population PK model to simulate sirolimus 
exposure, including concentrations at the time of hematologic or cholesterol lab draws, and 
maximum, trough, and average concentration for each day of an AE assessment (i.e., lab 
draw) or efficacy diagnosis (i.e., serum chemistry or biopsy-proven rejection). Simulations 
accounted for any changes in drug dosing during hospitalization. For each inpatient, we 
characterized observed and simulated concentrations as meeting goal, less than goal, or 
greater than goal according to the timing of the simulated sirolimus exposure in relationship 
to the time since transplant. More specifically, for patients 0 to <4 months post- transplant, 
an acceptable goal trough concentration is 10 to 15 μg/L; from 4 to 12 months post-
transplant, the goal is 16 to 24 μg/L; and for patients beyond 12 months post-transplant, the 
goal is 12 to 20 μg/L.3 Patients without a well-defined date of transplant in the electronic 
health record (EHR) were assigned to the late post-transplant group (>12 months).
Because we could not confirm patient-reported dosing for outpatients, we did not simulate 
exposure in this population. However, we determined whether individually observed 
concentrations were within the goal range based on time since transplant.
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For inpatients and outpatients, we performed Wilcoxon rank sum analyses, Fisher’s exact 
tests, and linear regression where appropriate, to determine the distribution of specific 
efficacy or AEs among patients who met, those who were above, and those who were below 
goal concentrations. Finally, we performed a sensitivity analysis using similar statistical 
methods. In this analysis, we used lower thresholds to define anemia (hematocrit ≤ 0.25) and 
thrombocytopenia (≤ 100 × 103/ml) to determine whether those predefined thresholds 
influenced our results.
RESULTS
Inpatient cohort characteristics and observed data
A total of 83 sirolimus blood concentrations were available from 27 adult renal transplant 
patients who were admitted to a Duke University Health System hospital during the study 
period (Table 1). On average, patients in our cohort were 49 months post-transplant (median 
[range] 34 months [0-202]), and the median sirolimus dose was 2 mg/day (range [1, 6]) for 
observed concentrations (Table 1). We identified a wide range of concentrations collected 
during the study period (median [range] 7.9 ng/mL [2.5-64.4]); however, 3 concentrations 
were below the limit of quantification and not included in the analyses. Only 2 inpatients 
were also taking ≥1 of the CYP3A4/5 interacting drugs of interest during the study period. 
Based on recommended sirolimus concentrations according to time since transplant, 9 
patients (15 [18%] concentrations) had observed concentrations within the goal range. 
Twenty-four patients (61 (73%) concentrations) were below the goal range, and 5 patients (7 
(8%) concentrations) were above the goal range. Only 1 patient had all concentrations within 
the goal range; 20 patients had all concentrations below or within the goal concentration 
range; the remaining 6 patients each had some concentrations below, within, and above the 
target range.
Outpatient cohort characteristics and observed data
During the study period, a total of 513 sirolimus concentrations were available from 96 
patients seen in a Duke University Health System outpatient clinic, and the median [range] 
time since transplant was 59 months [1-237]. Based on recommended sirolimus 
concentrations according to time since transplant, 29 patients (47 (9%) concentrations) were 
within the goal range, 75 patients (434 (84%) concentrations) were below the goal range, 
and 8 patients (8 (2%) concentrations) were above the goal range. Twenty-four (5%) 
observed concentrations (from 16 patients) were below the limit of quantification and were 
not included in further analyses.
Population PK model development
Based on visual inspection of PK data and review of the literature, we chose a two-
compartment model with first-order absorption and elimination. Because few samples from 
our population were obtained within the first 2-3 hours after dose, thereby precluding 
characterizing the absorption phase following drug administration, we used the parameter 
estimates of the absorption rate constant (2.18 h−1) and lag time (0.24) from a previous 
model and fixed them in our model.17 The model adequately described the observed 
sirolimus concentrations from the inpatient cohort. On preliminary scatter plots, BSV in 
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clearance appeared to be influenced by covariates, age and body weight. During the 
univariable covariate screen for clearance, we observed a statistically significant drop in 
OFV with the age covariate (see Table, Supplemental Digital Content 1, which summarizes 
the covariate model building process for sirolimus). The goodness of fit also improved after 
we included age in the final model. Scatter plots suggested no statistically significant 
correlations between covariates and volume of distribution.
Population PK model evaluation
The final model parameter estimates had good precision (Table 2). The relative standard 
errors around the parameter point estimates were 9 to 39%. The median bootstrap estimates 
were within 5% of original population estimates for all parameters. The 2.5th and 97.5th 
percentiles were narrow for all the parameters except BOV, which had a wider range. There 
were no obvious trends or model misspecification identified in the goodness of fit diagnostic 
plots for the final model (see Figure, Supplemental Digital Content 2, which expresses the 
final population PK model diagnostic plots). The standardized visual predictive check 
revealed a good fit of the observed sirolimus concentrations, as evidenced by the uniform 
distribution of calculated observation percentiles for each time point and only 9.8% of 
observed concentrations outside of the 90% prediction interval.
Relationship between observed or simulated sirolimus exposures and efficacy or AEs 
among inpatients and outpatients
Our analyses identified 2 notable findings in the inpatient population. Graft loss or rejection 
was more common among those with simulated trough concentrations above goal compared 
to those with simulated trough concentrations below goal (coeff [95% confidence interval]: 
0.32 [0.16, 0.48]). Decline in renal function was more common among those with simulated 
peak concentrations at the recommended trough goal compared to peak concentrations 
below the goal range (0.11 [0.04, 0.18]). Initially, we observed statistically significant 
associations between sirolimus concentrations and anemia (p=0.017 for observed 
concentrations) or thrombocytopenia (0.029 for observed, 0.040 for simulated trough, 0.002 
for simulated average concentrations); however, the associations were no longer statistically 
significant when we further evaluated these relationships with sensitivity testing using lower 
thresholds for classification of anemia and thrombocytopenia. We did not identify other 
statistically significant associations between the distribution of AEs and drug concentrations. 
We found no statistically significant associations between concentrations and AEs among 
outpatients.
DISCUSSION
Our combined method proved useful in the development of a population PK model using 
EHR data, simulation of drug exposure, and determination of some exposure-AE 
relationships in our population. Our PK model provided reasonable parameter estimates of 
volume of distribution and clearance compared to those in the literature. Observed 
differences between our parameter estimate for volume of distribution and existing 
estimates, may be related to unmeasured differences in population characteristics, including: 
1) administration with food and food content, 2) administered drug formulation, and 3) body 
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fat composition, given the high partition coefficient of sirolimus that increases the likelihood 
of a higher volume of distribution with high body fat composition.18-21 Differences in 
apparent oral clearance between our population and others may be related to variability in 
cyclosporine use and exposure, differences in extent of CYP3A4 and CYP3A5 expression, 
other disease states (e.g., liver disease and cancer), and other drug interactions.18,19,22,23 
Unlike other studies that have developed population PK models, we identified age as an 
important covariate for apparent clearance. This finding may reflect the relatively more 
advanced median age of patients in our study (59, range 29 to 72 compared to 48.6, range 20 
to 69), and potential influences of age on CYP3A4 activity.17,24,25
We successfully used our model to simulate drug exposures not generally identified with 
routine therapeutic drug monitoring. While the majority of patients in our cohort were 
without adverse event despite concentrations below goal range, our combined methodology 
allowed us to identify increased frequency of graft loss or rejection among those with 
simulated trough concentrations above compared to those at goal. Given the average time 
since transplant of patients in our cohort, we suspect the observed relationship between 
elevated concentrations and the composite efficacy outcome, reflects patients with graft 
dysfunction due to chronic allograft nephropathy who may have other reasons for poor drug 
clearance (i.e., liver dysfunction). Alternatively, such patients may have recently transitioned 
from a calcineurin inhibitor to sirolimus in order to attempt graft rescue or to minimize 
additional nephrotoxicity, but have not yet achieved target dosing.26-28
We also identified a relationship between decline in renal function and peak sirolimus 
concentrations within recommended trough goals. The association between inadequate 
immunosuppression and decline in renal function for renal transplant patients is well 
documented and often represents graft dysfunction secondary to rejection.29-31 Conversely, a 
decline in renal function associated with high sirolimus concentrations may represent drug 
toxicity.32 Although previous studies have documented limited renal toxicity associated with 
sirolimus, few have evaluated toxicity with sirolimus concentrations or determined the effect 
of sirolimus independent of cyclosporine.32,33 Our observed association between peak 
concentrations and decline in renal function is a unique finding in our data. Toxicity of 
immunosuppressants and other drugs (e.g., antibiotics) is usually attributed to: 1) cumulative 
exposures, 2) average exposures, or 3) area under the concentration time curves.34,35 
Although many potential reasons exist for renal dysfunction in hospitalized adult patients, a 
true relationship between peak sirolimus concentrations and nephrotoxicity, particularly in 
patients in the late transplant phase, could impact the post-dose timing of therapeutic drug 
monitoring.
Although useful in some aspects, our combined methodology was limited in its ability to 
fully characterize the exposure-AE relationship for all AEs of interest. For example, 
application of our method to hematologic AEs likely produced spurious results. We only 
observed relationships in the inpatient population with a relatively small sample size and 
numerous other reasons for thrombocytopenia and anemia (Figure1); results were no longer 
present with sensitivity testing; and the directionality of results were contradictory and 
appeared biologically implausible, or confounded by other clinical factors. Further, much of 
the existing evidence suggests that hematologic abnormalities are most commonly present in 
Zimmerman et al. Page 7
Ther Drug Monit. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the first 2 weeks after transplant and would be much less likely in our late-transplant 
population.36 Our use of electronic health records also limited our ability to identify other 
potential AEs such as gingival hyperplasia or evaluate other likely relevant covariates (e.g., 
serum albumin) in our PK model.
Estimation of the sirolimus exposure-response relationships for all known sirolimus AEs 
was likely limited by our study population. Although reflective of prescribing practice for 
sirolimus at our hospital during the specified time period, our sample size was small and 
mostly >1 year post transplant. These factors likely decreased the propensity to observe 
AEs, limited our ability to evaluate effects of interacting drugs in our PK model, and limited 
the number of patients with efficacy failure. Second, our study does not account for trends 
over time in sirolimus exposure that may be more definitively associated with AEs. Next, we 
targeted trough concentrations identified in the product label and literature for patients not 
receiving concomitant immunosuppression; goal concentrations used in real-world practice 
are often dependent upon both the time since transplant and the baseline risk for rejection of 
the individual patient.(3) Based on retrospective review, we were unable to identify 
individual patient risk status. Given the limited number of patients who had a sirolimus 
concentration and were therefore included in our cohort, our population may be biased 
towards patients suspected to have sirolimus concentrations out of the targeted range. 
Further, the goals for peak and average sirolimus concentrations have not previously been 
established; comparison of these values to trough values allowed a consistent point of 
reference, but may not reflect the most relevant point of reference for peak and average 
concentrations, given variable effects of drug PK on each of these values.
CONCLUSIONS
A combined approach using therapeutic drug monitoring and other data from the EHR, and 
PK modeling identified important exposure-AE relationships and revealed that the majority 
of patients did well with concentrations below goal range, but was limited in its ability to 
characterize all exposure-response relationships. If applied to a larger cohort who is at high 
risk for drug toxicity and efficacy failure, our combined approach may prove to be an 
efficient and inexpensive way to establish the therapeutic index of drugs, particularly when 
prospective data is limited.
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Figure 1. 
Boxplots of sirolimus exposure in patients with and without anemia from inpatient data (A), 
simulated data (B), and outpatient data (C). Boxplots of sirolimus exposure in patients with 
and without thrombocytopenia from inpatient data (D), simulated data (E), and outpatient 
data (F). Boxplots of sirolimus exposure in patients with and without graft loss or rejection 
from inpatient data (G) and simulated data (H). Boxplots of sirolimus exposure in patients 
with and without decline in renal function from inpatient data (I) and simulated data (J). 
Sirolimus exposure was defined as measured sirolimus concentrations on the day of AEs in 
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inpatient and outpatient data. Sirolimus exposure was defined as average sirolimus 
concentration on the day of AE in simulated data.
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Table 1
Inpatient demographics
Variable Median (range) or N (%)
N 27
Age (years) 56 (31 - 67)
Body weight (kg) 74 (51 - 124)
Female 12 (44)
Race
 White 16 (59)
 Black or African American 10 (37)
 Unknown or not reported 1 (4)
Sirolimus dose (mg/day) 2 (1, 6)
Time post-transplant (months) 34 (0-202)
Hematocrit 0.30 (0.22-0.44)
Platelet count (× 103/ml) 179 (39-570)
White blood cell count (× 103/ml) 7.2 (1.2-22.3)
Serum creatinine (mg/dl) 2.0 (0.7-9.0)
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Table 2
Parameter estimates for the final sirolimus population PK model
Parameter Estimate RSE
(%)
Parameter estimates reported
in the literaturea,b
Structural Model
Apparent oral clearance (L/h)c 7.4 9 14.1 24; 8.91 17
Central volume of distribution (L) 128 29 219 24; 112.9 17
Apparent distributional clearance (L/h) 27.8 39 37.8 24
Peripheral volume of distribution (L) 278 29 297 24; 45217
Exponent of age effect on clearancec −1.02 28
Absorption rate constant (1/h) 2.18d - 2.18 17
Absorption lag time (h) 0.24d - 0.24 17
Between subject variability (%CV)
Apparent oral clearance (L/h) 22.7 32 23.8, 22; 13.2 17; 48.424
Between-occasion Variability (%CV)
Apparent oral clearance (L/h) 26.1 36
Residual Variability (%)
Proportional error 33.8 14
aValues from reference 18 are presented as mean values
b
Renal transplant patients
cApparent oral clearance (L/h) = (Individual age in years/Median age of the population)
d
Parameter values for absorption rate constant and lag time were obtained from a previously published model and fixed in our model
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